CN115209952B - 经取代的吡唑并嘧啶及其用途 - Google Patents

经取代的吡唑并嘧啶及其用途 Download PDF

Info

Publication number
CN115209952B
CN115209952B CN202180018763.7A CN202180018763A CN115209952B CN 115209952 B CN115209952 B CN 115209952B CN 202180018763 A CN202180018763 A CN 202180018763A CN 115209952 B CN115209952 B CN 115209952B
Authority
CN
China
Prior art keywords
pyrazolo
pyrazol
pyrimidin
morpholino
tolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180018763.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115209952A (zh
Inventor
M·D·罗森
Jr·R·A·迦勒莫
W·梁
B·科佩克
I·Y·崔
J·罗德岛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wikianalytics Ltd
Original Assignee
Wikianalytics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wikianalytics Ltd filed Critical Wikianalytics Ltd
Publication of CN115209952A publication Critical patent/CN115209952A/zh
Application granted granted Critical
Publication of CN115209952B publication Critical patent/CN115209952B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180018763.7A 2020-01-13 2021-01-12 经取代的吡唑并嘧啶及其用途 Active CN115209952B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062960412P 2020-01-13 2020-01-13
US62/960,412 2020-01-13
US202063074388P 2020-09-03 2020-09-03
US63/074,388 2020-09-03
PCT/US2021/013077 WO2021146192A1 (en) 2020-01-13 2021-01-12 Substituted pyrazolo-pyrimidines and uses thereof

Publications (2)

Publication Number Publication Date
CN115209952A CN115209952A (zh) 2022-10-18
CN115209952B true CN115209952B (zh) 2025-05-30

Family

ID=74626126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180018763.7A Active CN115209952B (zh) 2020-01-13 2021-01-12 经取代的吡唑并嘧啶及其用途

Country Status (15)

Country Link
US (1) US12486274B2 (https=)
EP (1) EP4090426B1 (https=)
JP (1) JP7744350B2 (https=)
KR (1) KR20220140515A (https=)
CN (1) CN115209952B (https=)
AU (1) AU2021207804A1 (https=)
BR (1) BR112022013488A2 (https=)
CA (1) CA3167339A1 (https=)
CL (1) CL2022001887A1 (https=)
CO (1) CO2022011258A2 (https=)
IL (1) IL294504A (https=)
MX (1) MX2022008627A (https=)
PH (1) PH12022551623A1 (https=)
TW (1) TWI885039B (https=)
WO (1) WO2021146192A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
US20240018151A1 (en) * 2020-10-19 2024-01-18 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
TW202313619A (zh) * 2021-06-01 2023-04-01 美商邊際分析公司 稠合雙環雜環化合物及其用途
US20250353852A1 (en) * 2021-12-08 2025-11-20 Kineta, Inc. Compounds and compositions that inhibit pikfyve
US20250388582A1 (en) * 2022-07-13 2025-12-25 Ildong Pharmaceutical Co., Ltd. Novel bicyclic heteroaryl compound and use thereof
WO2024168016A1 (en) * 2023-02-10 2024-08-15 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CN120093763A (zh) * 2025-03-25 2025-06-06 上海天龙生物科技有限公司 治疗前列腺疾病和腺体类散结节的药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175906A1 (en) * 2017-03-24 2018-09-27 Nanosyn, Inc. Fused triazolo-pyrimidine compounds having useful pharmaceutical application
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6384032B1 (en) 1999-06-17 2002-05-07 Shionogi Bioresearch Corp. Inhibitors of IL-12 production
EP1185528A4 (en) 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
US6680315B2 (en) 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7557110B2 (en) 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
WO2005000404A2 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
TWI376370B (en) 2003-07-23 2012-11-11 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
AR045582A1 (es) 2003-09-05 2005-11-02 Neurogen Corp Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1
AU2004272437A1 (en) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
AU2004289304A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
AU2004289303A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
WO2006007532A2 (en) 2004-07-01 2006-01-19 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
DE502005008916D1 (de) 2004-07-23 2010-03-11 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
KR20070057965A (ko) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
AU2005306471B2 (en) 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
JP2006160628A (ja) 2004-12-03 2006-06-22 Ishihara Sangyo Kaisha Ltd アデノシンＡ２ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
KR20140018997A (ko) 2005-01-07 2014-02-13 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
EP1846388A4 (en) 2005-01-25 2011-12-07 Synta Pharmaceuticals Corp THIOPHEN COMPOUNDS FOR IGNITIONS AND THE IMMUNE SYSTEM APPLICATIONS
PL1848435T3 (pl) 2005-01-25 2016-08-31 Synta Pharmaceuticals Corp Związki przeciwko zapaleniom i zastosowania związane z odpornością
US7473694B2 (en) 2005-03-17 2009-01-06 Teijin Pharma Limited Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
BRPI0614884A2 (pt) 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
AR057979A1 (es) 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
WO2007071688A1 (en) 2005-12-22 2007-06-28 L'oréal Composition for dyeing keratin fibres with a tetraazapentamethine cationic direct dye, a particular oxidation base and a coupler
TW200806641A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted aromatic compounds for inflammation and immune-related uses
US7816535B2 (en) 2006-01-25 2010-10-19 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
US20070254926A1 (en) 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
EP1829879A1 (en) 2006-02-10 2007-09-05 Cellzome (UK) Ltd. Amino pyrimidine compounds for the treatment of inflammatory disorders
AU2007227210A1 (en) 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
EP2003131A4 (en) 2006-04-04 2009-12-16 Taisho Pharmaceutical Co Ltd AMINOPYRROLIDINE COMPOUND
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
KR20090028819A (ko) 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
RU2475478C2 (ru) 2006-08-21 2013-02-20 Синта Фармасьютиклз Корп. Соединения для лечения пролиферативных расстройств
US8785451B2 (en) 2006-08-21 2014-07-22 Synta Pharmaceuticals Corp. Compounds for the treatment of proliferative disorders
US8497272B2 (en) 2006-08-21 2013-07-30 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
US20080207641A1 (en) 2006-11-13 2008-08-28 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
JP2010519206A (ja) 2007-02-16 2010-06-03 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫関連使用のための置換縮合環化合物
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
US8093425B2 (en) 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
EP2164842A2 (en) 2007-05-24 2010-03-24 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2009007753A2 (en) 2007-07-11 2009-01-15 Astrazeneca Ab 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
TW200906818A (en) 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
CA2695143A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Heterocycle-aryl compounds for inflammation and immune-related uses
WO2009017831A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
CA2695148A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses
US8729111B2 (en) 2007-08-07 2014-05-20 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
US8324219B2 (en) 2007-09-20 2012-12-04 Synta Pharmaceuticals Corp. Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
CN101970440A (zh) 2007-11-28 2011-02-09 先灵公司 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类
US20110052643A1 (en) 2008-01-07 2011-03-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2009100406A2 (en) 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
AU2009300316A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2009300317A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2009300318A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
JP5578490B2 (ja) * 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
SG179083A1 (en) 2009-09-11 2012-04-27 Cylene Pharmaceuticals Inc Pharmaceutically useful heterocycle-substituted lactams
WO2011081171A1 (ja) 2009-12-28 2011-07-07 味の素株式会社 スクリーニング方法
ES2540867T3 (es) 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
PT3012258T (pt) 2010-06-24 2018-12-14 Gilead Sciences Inc Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral
WO2012027240A1 (en) 2010-08-23 2012-03-01 Schering Corporation Fused tricyclic inhibitors of mammalian target of rapamycin
WO2012037116A2 (en) 2010-09-13 2012-03-22 The Children's Hospital Of Philadelphia Common and rare genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof for the treatment and diagnosis of the same
WO2012047569A1 (en) 2010-09-28 2012-04-12 Schering Corporation Fused tricyclic inhibitors of mammalian target of rapamycin
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
EP2638032A1 (en) 2010-11-09 2013-09-18 Synta Pharmaceuticals Corp. Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
US9234885B2 (en) 2011-01-25 2016-01-12 Albert Einstein College Of Medicine, Inc. Methods and assays for treating filoviridae infections
WO2012112245A1 (en) 2011-02-14 2012-08-23 Beth Israel Deaconess Medical Center, Inc. Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
JP5531066B2 (ja) 2011-08-24 2014-06-25 田辺三菱製薬株式会社 ピラゾロピリミジン化合物及びｐｄｅ１０阻害剤としてのその使用
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
JP2014532656A (ja) 2011-10-28 2014-12-08 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のための化合物
AU2013249280B2 (en) 2012-04-17 2017-10-12 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
CN103242341B (zh) 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
EP2857004B1 (en) 2013-10-07 2018-07-04 The Procter and Gamble Company Hair straightening method involving reducing sugars
CN104557872B (zh) 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
KR102320190B1 (ko) 2014-01-24 2021-11-03 에이아이 테라퓨틱스, 인코포레이티드 아필리모드 조성물 및 이를 사용하기 위한 방법
PL407081A1 (pl) 2014-02-05 2015-08-17 Celon Pharma Spółka Akcyjna Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK-2
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
EA035646B1 (ru) 2014-08-29 2020-07-21 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
RU2739992C2 (ru) 2014-11-07 2020-12-30 ЭйАй ТЕРАПЬЮТИКС, ИНК. Композиции апилимода и способы их применения в лечении колоректального рака
CA2966359A1 (en) 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
WO2016091774A1 (en) 2014-12-08 2016-06-16 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
WO2016112072A1 (en) 2015-01-07 2016-07-14 President And Fellows Of Harvard College Methods for treating or preventing ebolavirus or marburgvirus infections
WO2016118709A1 (en) 2015-01-23 2016-07-28 Lam Therapeutics, Inc. Anti-viral compositions containing pikfyve inhibitors and use thereof
WO2016126707A1 (en) 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
CN105963300B (zh) 2015-03-13 2019-06-11 中国人民解放军军事医学科学院放射与辐射医学研究所 PIKfyve抑制剂抗辐射损伤的用途
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
US20180078561A1 (en) 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
WO2016161145A1 (en) 2015-03-31 2016-10-06 Dana-Farber Cancer Institute, Inc. Stk4 inhibitors for treatment of hematologic malignancies
PL236355B1 (pl) 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
US10758545B2 (en) 2015-06-25 2020-09-01 University Of Southern California Methods to treat neurological diseases
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
EP3324974B1 (en) 2015-07-24 2022-06-08 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods for treating diseases, and methods for preparing compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2017040971A1 (en) 2015-09-03 2017-03-09 Biomarin Pharmaceutical Inc. Methods of using inhibitors of pikfyve for the treatment of lysosomal storage disorders and neurodegenerative diseases
CA2999177A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
EP3380476B1 (en) 2015-11-23 2020-09-30 Council of Scientific and Industrial Research Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
WO2017127661A1 (en) 2016-01-21 2017-07-27 Lam Therapeutics, Inc. Biomarkers for treating cancer with apilimod
CN105820175B (zh) 2016-04-13 2019-09-20 四川大学 一种噻吩并嘧啶类化合物及其制备方法和应用
US20180036420A1 (en) 2016-08-03 2018-02-08 Lam Therapeutics, Inc. Methods for enhancing the delivery of molecules across the blood brain barrier
US20180050041A1 (en) 2016-08-19 2018-02-22 Lam Therapeutics, Inc. Compositions and Methods for Treating Niemann Pick C Disease
RU2019108279A (ru) 2016-08-25 2020-09-25 ЭйАй ТЕРАПЬЮТИКС, ИНК. Композиции, содержащие ингибиторы pikfyve, и способы, связанные с ингибированием сигнального пути rank
GB201616237D0 (en) 2016-09-23 2016-11-09 Univ Oslo Hf Modulation of function of immune effector cells
BR112019007214A2 (pt) 2016-10-12 2019-07-02 Ai Therapeutics Inc composições do apilimode e métodos para uso do mesmo no tratamento do mal de alzheimer
JOP20190113A1 (ar) 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
KR102654864B1 (ko) 2016-11-18 2024-04-05 삼성전자주식회사 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물
US20210062160A1 (en) 2017-01-09 2021-03-04 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Therapeutic and immunomodulatory bacteriophage formulations and methods for making and using them
US10021905B1 (en) 2017-01-17 2018-07-17 Modern Vital Inc. Smoking apparatus with a pump and a method of using same
US20190070166A1 (en) 2017-09-02 2019-03-07 Richard Postrel Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
WO2018138106A1 (en) 2017-01-27 2018-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
CN106957303B (zh) 2017-02-28 2019-06-04 中山大学 选择性Aurora A激酶抑制活性的喹唑啉衍生物及其制备方法以及应用
US10702534B2 (en) 2017-03-31 2020-07-07 AI Therapeutics, Inc. Compositions and methods relating to the radioprotective effects of apilimod
CN107163061A (zh) 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
WO2019027765A1 (en) 2017-08-02 2019-02-07 Northwestern University SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2019108665A1 (en) 2017-12-01 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Autophagy modulators for use in treating cancer
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TW202000205A (zh) 2018-02-21 2020-01-01 美商Ａｉ治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
CN108586486B (zh) 2018-06-19 2021-03-02 四川大学 一种芳基取代噻吩并嘧啶类化合物的制备方法
EP3793544B1 (en) 2018-06-19 2023-09-20 Armaceutica, Inc Bifunctional compositions for the treatment of cancer
EP3817736A4 (en) 2018-07-05 2021-07-28 Mayo Foundation for Medical Education and Research PIKFYVE INHIBITORS
GB2576039B (en) 2018-08-02 2021-01-06 Ip2Ipo Innovations Ltd A joint
CN110835345A (zh) 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
US20210033597A1 (en) 2018-12-31 2021-02-04 AcuraStem Incorporated Method for identifying effective treatments against neurodegenerative disorders
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
AU2020270981A1 (en) 2019-04-10 2021-11-04 Cornell University PIP4Ks suppress insulin signaling and enhance immune function through a catalytic-independent mechanism
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
AR119934A1 (es) 2019-09-12 2022-01-19 Ai Therapeutics Inc Inhibidores de pikfyve para terapia contra el cáncer
JP7635228B2 (ja) 2019-11-08 2025-02-25 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
US20220409617A1 (en) 2019-11-13 2022-12-29 The Regents Of The University Of California Drug Formulations and Methods of Treatment for Metabolic Disorders
TW202134245A (zh) 2019-12-05 2021-09-16 美商邊際分析公司 稠合三環雜環化合物及其用途
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
WO2021155067A1 (en) 2020-01-28 2021-08-05 University Of Southern California Compositions and methods to treat neurological diseases
CA3170133A1 (en) 2020-02-07 2021-08-12 AI Therapeutics, Inc. Anti-viral compositions and methods of use
EP4103281A1 (en) 2020-02-11 2022-12-21 Acurastem Inc. Pikfyve kinase inhibitors
WO2021183439A1 (en) 2020-03-09 2021-09-16 Verge Analytics, Inc. Substituted furo[3,2-d]pyrimidines and uses thereof
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
US20210338683A1 (en) 2020-05-01 2021-11-04 AcuraStem, Inc. Treatment of viral infections with combination of pikfyve kinase inhibitors and tmprss-2 inhibitors
EP4161523A4 (en) 2020-06-03 2024-07-03 Yumanity Therapeutics, Inc. BICYCLIC HETEROARENES AND METHODS OF USE THEREOF
US20240150358A1 (en) 2020-06-03 2024-05-09 Kineta, Inc. Purines and methods of their use
WO2021247859A1 (en) 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
WO2021252895A2 (en) 2020-06-11 2021-12-16 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
IL299804A (en) 2020-07-13 2023-03-01 Beijing Tide Pharmaceutical Co Ltd Pyrazolopyrimidine compounds for use as ATR kinase inhibitors
US20240018151A1 (en) 2020-10-19 2024-01-18 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
US20230364084A1 (en) 2020-10-28 2023-11-16 The Regents Of The University Of Michigan Methods for preventing or treating conditions related to pikfyve activity
WO2022094615A1 (en) 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
WO2022235971A2 (en) 2021-05-06 2022-11-10 Systems Oncology, Llc Compositions for inhibiting growth of targeted cells
IL309143A (en) 2021-06-11 2024-02-01 Orphai Therapeutics Inc Stabilized apilimod compositions and uses thereof
US12104159B2 (en) 2021-06-22 2024-10-01 AcuraStem Incorporated PIKFYVE antisense oligonucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175906A1 (en) * 2017-03-24 2018-09-27 Nanosyn, Inc. Fused triazolo-pyrimidine compounds having useful pharmaceutical application
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS

Also Published As

Publication number Publication date
US20230133203A1 (en) 2023-05-04
PH12022551623A1 (en) 2023-11-29
KR20220140515A (ko) 2022-10-18
JP7744350B2 (ja) 2025-09-25
JP2023510874A (ja) 2023-03-15
WO2021146192A1 (en) 2021-07-22
BR112022013488A2 (pt) 2022-09-13
TW202140483A (zh) 2021-11-01
CO2022011258A2 (es) 2022-09-30
CN115209952A (zh) 2022-10-18
TWI885039B (zh) 2025-06-01
AU2021207804A1 (en) 2022-09-01
CA3167339A1 (en) 2021-07-22
CL2022001887A1 (es) 2023-04-10
US12486274B2 (en) 2025-12-02
EP4090426B1 (en) 2025-12-31
IL294504A (en) 2022-09-01
EP4090426A1 (en) 2022-11-23
MX2022008627A (es) 2022-11-08

Similar Documents

Publication Publication Date Title
CN115209952B (zh) 经取代的吡唑并嘧啶及其用途
JP7010935B2 (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換ヘテロ環
CN103797011B (zh) 作为c-Kit激酶抑制剂的化合物和组合物
CN109071546B (zh) 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
JP2022071046A (ja) Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
JP6964576B2 (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
JP2021534139A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
TW202140496A (zh) 經取代嘧啶及其用途
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
CN115989228A (zh) 杂环化合物
TW202134245A (zh) 稠合三環雜環化合物及其用途
US12428403B2 (en) N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
CN118488953A (zh) 用作单酰基甘油脂肪酶抑制剂的双环杂环化合物
TW202333664A (zh) 新穎雜環化合物
HK40075899A (en) Substituted pyrazolo-pyrimidines and uses thereof
TW202448438A (zh) 吡唑3h-咪唑并(4,5-b)吡啶化合物及其用途
HK1258157B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075899

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant